Skip to content

2APharma

Biopharmaceutical company

  • Home
  • ABOUT US
  • VACCINE PLATFORM
  • PIPELINE
    • OVERVIEW
    • 2AP01
    • 2AP02
    • 2AP03
    • 2AP05
    • 2AP07
  • NEWS
  • CONTACT US

June 5, 2020

2AP07

OVERVIEW:

  • Early stage project to develop a therapeutic head and neck cancer vaccine.
  • Project partly funded by the EU Eurostars programme.
  • Collaboration with the Danish Technological Institute and DNASense.
  • Head and neck cancers represent the sixth most common cancer worldwide, resulting in more than 350,000 deaths/year. Our AAVLP-HNC vaccine uses our mimotope selection technology and has the potential to minimize side effects, improve efficacy, and markedly reduce treatment costs. This will address an unmet medical need and benefit cancer patients as well as reduce healthcare expenses. In addition, our combination of advanced technologies will establish a versatile platform for developing further vaccines without knowing the antigen.

    Back

    Denmark

    2A Pharma ApS
    Niels Jernes Vej 10
    9220 Aalborg Øst
    Denmark

    CVR No.: 3939 1597
    VAT No.: DK 3939 1597

    Sweden

    2A Pharma AB
    Södergatan 3
    211 34 Malmö
    Sweden

    Registration No.: 559090-2788
    VAT No.: SE55 9090 2788 01

    Pipeline

  • 2AP01 HPV
  • 2AP02 Breast Cancer
  • 2AP03 Allergic Diseases
  • 2AP04 Alzheimer's
  • 2AP05 Autoimmune Diseases
  • 2AP06 HIV
  • 2AP07 Head and Neck Cancer
  • Subscribe to our newsletters

    Contact

    +45 7214 6700
    info@2apharma.com